| Autor: |
Santiago Sánchez-Sosa, Carlos Rodríguez-Medina, Ruth Stuckey, Yanira Florido, Guillermo Santana, Jesús María González Martín, Naylén Cruz-Cruz, Melissa Torres-Ochando, Rosa Fernández, Nuria Sánchez-Farías, Antonia Cionfrini, Teresa Molero Labarta, María Teresa Gomez-Casares, Cristina Bilbao-Sieyro |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Journal of Cancer. 13(4) |
| ISSN: |
1837-9664 |
| Popis: |
Recent advances in sequencing technologies and genomics have led to the development of several targeted therapies such as BCL2 and Bromodomain and extra-terminal (BET) protein inhibitors for a more personalized treatment of patients with acute myeloid leukemia (AML), yet the majority of patients still receive standard induction chemotherapy. The molecular profiles of patients who are likely to respond to induction therapy and novel directed therapies remain to be determined. The expression of AML-related genes that are targeted by novel therapies such as |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
